Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

Mahmud SM, Bozat-Emre S, Mostaço-Guidolin LC, Marrie RA.

Emerg Infect Dis. 2018 Jul;24(7):1267-1274. doi: 10.3201/eid2407.161783.

PMID:
29912696
2.

The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases.

Enns MW, Bernstein CN, Kroeker K, Graff L, Walker JR, Lix LM, Hitchon CA, El-Gabalawy R, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

PLoS One. 2018 Jun 7;13(6):e0198975. doi: 10.1371/journal.pone.0198975. eCollection 2018.

3.

Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.

Maranzano J, Till C, Assemlal HE, Fonov V, Brown R, Araujo D, O'Mahony J, Yeh EA, Bar-Or A, Marrie RA, Collins L, Banwell B, Arnold DL, Narayanan S; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952. [Epub ahead of print]

PMID:
29852831
4.

Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study.

McKay KA, Marrie RA, Fisk JD, Patten SB, Tremlett H.

Neuroepidemiology. 2018 May 15;51(1-2):1-10. doi: 10.1159/000488799. [Epub ahead of print]

PMID:
29763935
5.

Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.

Marrie RA, Montalban X.

Mult Scler. 2018 Apr;24(5):558-562. doi: 10.1177/1352458518767323. No abstract available.

PMID:
29692224
6.

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):789-800. doi: 10.1212/WNL.0000000000005345.

PMID:
29686117
7.

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):777-788. doi: 10.1212/WNL.0000000000005347.

PMID:
29686116
8.

Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2018 Mar-Apr;20(2):76-84. doi: 10.7224/1537-2073.2016-110.

9.

The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.

Bernstein CN, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott J, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy068. [Epub ahead of print]

PMID:
29668911
10.

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H.

J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493. doi: 10.1136/jnnp-2017-317493. [Epub ahead of print]

PMID:
29602795
11.

Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan.

Al-Sakran LH, Marrie RA, Blackburn DF, Knox KB, Evans CD.

Can J Neurol Sci. 2018 May;45(3):295-303. doi: 10.1017/cjn.2017.301. Epub 2018 Mar 20.

PMID:
29557321
12.

Temporal trends in multiple sclerosis prevalence and incidence in a large population.

Rotstein DL, Chen H, Wilton AS, Kwong JC, Marrie RA, Gozdyra P, Krysko KM, Kopp A, Copes R, Tu K.

Neurology. 2018 Apr 17;90(16):e1435-e1441. doi: 10.1212/WNL.0000000000005331. Epub 2018 Mar 16.

PMID:
29549225
13.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.

PMID:
29523642
14.

Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease.

Litster B, Bernstein CN, Graff LA, Walker JR, Fisk JD, Patten SB, Bolton JM, Sareen J, El-Gabalawy R, Marrie RA.

Inflamm Bowel Dis. 2018 Mar 7. doi: 10.1093/ibd/izy032. [Epub ahead of print]

PMID:
29522100
15.

Lower prevalence of multiple sclerosis in First Nations Canadians.

Marrie RA, Leung S, Yu N, Elliott L.

Neurol Clin Pract. 2018 Feb;8(1):33-39. doi: 10.1212/CPJ.0000000000000418. Review.

PMID:
29517055
16.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324
17.

Factors associated with excessive sitting time in multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler Relat Disord. 2018 Apr;21:71-77. doi: 10.1016/j.msard.2018.02.009. Epub 2018 Feb 10.

PMID:
29477021
18.

Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis.

Marrie RA, Hitchon CA, Walld R, Patten SB, Bolton JM, Sareen J, Walker JR, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; Canadian Institutes of Health Research Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Arthritis Care Res (Hoboken). 2018 Feb 13. doi: 10.1002/acr.23539. [Epub ahead of print]

PMID:
29438604
19.

Maternal and fetal risks of natalizumab exposure in utero: A fine balance.

Marrie RA.

Neurology. 2018 Mar 6;90(10):443-444. doi: 10.1212/WNL.0000000000005075. Epub 2018 Feb 7. No abstract available.

PMID:
29438040
20.

The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.

Lavery AM, Collins BN, Waldman AT, Hart CN, Bar-Or A, Marrie RA, Arnold D, O'Mahony J, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089. [Epub ahead of print]

PMID:
29393768
21.

National estimates of self-reported sitting time in adults with multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler J Exp Transl Clin. 2018 Jan 19;4(1):2055217318754368. doi: 10.1177/2055217318754368. eCollection 2018 Jan-Mar.

22.

Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Mar - Apr;51:71-78. doi: 10.1016/j.genhosppsych.2018.01.003. Epub 2018 Jan 11.

PMID:
29353127
23.

Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study.

Marrie RA, Graff L, Walker JR, Fisk JD, Patten SB, Hitchon CA, Lix LM, Bolton J, Sareen J, Katz A, Berrigan LI, Marriott JJ, Singer A, El-Gabalawy R, Peschken CA, Zarychanski R, Bernstein CN.

JMIR Res Protoc. 2018 Jan 17;7(1):e15. doi: 10.2196/resprot.8794.

24.
25.

Effects of physical comorbidities on disability progression in multiple sclerosis.

Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell T, Stadnyk K, Carruthers R, Wolfson C, Warren S, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.

PMID:
29298855
26.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
27.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
28.

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis.

Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott JJ, Bernstein CN.

Mult Scler Relat Disord. 2018 Feb;20:9-15. doi: 10.1016/j.msard.2017.12.007. Epub 2017 Dec 16.

29.

Discriminative ability of quality of life measures in multiple sclerosis.

Fiest KM, Greenfield J, Metz LM, Patten SB, Jetté N, Marrie RA.

Health Qual Life Outcomes. 2017 Dec 21;15(1):246. doi: 10.1186/s12955-017-0828-0.

30.

Clinical Profile of Persons with Multiple Sclerosis Across the Continuum of Care.

Turcotte LA, Marrie RA, Patten SB, Hirdes JP.

Can J Neurol Sci. 2018 Mar;45(2):188-198. doi: 10.1017/cjn.2017.274. Epub 2017 Dec 18.

PMID:
29251260
31.

Validation of an algorithm to detect severe MS relapses in administrative health databases.

Marriott JJ, Chen H, Fransoo R, Marrie RA.

Mult Scler Relat Disord. 2018 Jan;19:134-139. doi: 10.1016/j.msard.2017.11.022. Epub 2017 Dec 2.

PMID:
29223870
32.

Diet quality is associated with disability and symptom severity in multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox R, Marrie RA.

Neurology. 2018 Jan 2;90(1):e1-e11. doi: 10.1212/WNL.0000000000004768. Epub 2017 Dec 6.

PMID:
29212827
33.

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?

Marrie RA.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e421. doi: 10.1212/NXI.0000000000000421. eCollection 2018 Jan. No abstract available.

34.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

PMID:
29185555
35.

Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

BMC Res Notes. 2017 Nov 25;10(1):619. doi: 10.1186/s13104-017-2958-1.

36.

Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Neurology. 2017 Dec 12;89(24):2455-2461. doi: 10.1212/WNL.0000000000004716. Epub 2017 Nov 8.

PMID:
29117961
37.

Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Epidemiol Psychiatr Sci. 2017 Nov 3:1-10. doi: 10.1017/S2045796017000579. [Epub ahead of print]

PMID:
29098977
38.

Increased relapse rate during pregnancy and postpartum in neuromyelitis optica.

Banwell B, Marrie RA.

Neurology. 2017 Nov 28;89(22):2220-2221. doi: 10.1212/WNL.0000000000004721. Epub 2017 Nov 1. No abstract available.

PMID:
29093071
39.

Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Fallata A, Salter A, Tyry T, Cutter GR, Marrie RA.

Int J MS Care. 2017 Sep-Oct;19(5):240-246. doi: 10.7224/1537-2073.2016-065.

40.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

41.

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study.

Zhang T, Kingwell E, Zhu F, Petkau J, Kastrukoff LF, Marrie RA, Tremlett H, Evans C.

BMJ Open. 2017 Sep 29;7(9):e018612. doi: 10.1136/bmjopen-2017-018612.

42.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584
43.

Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?

Marrie RA, Beck CA.

Neurology. 2017 Oct 10;89(15):1538-1539. doi: 10.1212/WNL.0000000000004506. Epub 2017 Sep 13. No abstract available.

PMID:
28904085
44.

Caught in a no-win situation: discussions about CCSVI between persons with multiple sclerosis and their neurologists - a qualitative study.

Driedger SM, Maier R, Marrie RA, Brouwers M.

BMC Neurol. 2017 Sep 7;17(1):176. doi: 10.1186/s12883-017-0954-7.

45.

Increased incidence of psychiatric disorders in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

J Psychosom Res. 2017 Oct;101:17-23. doi: 10.1016/j.jpsychores.2017.07.015. Epub 2017 Aug 1.

46.

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.

Melesse DY, Marrie RA, Blanchard JF, Yu BN, Evans C.

Patient Prefer Adherence. 2017 Jun 28;11:1093-1101. doi: 10.2147/PPA.S138263. eCollection 2017.

47.

Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.

McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H.

Neuroepidemiology. 2017;48(3-4):124-130. doi: 10.1159/000477771. Epub 2017 Jul 7.

PMID:
28683461
48.

Depression in multiple sclerosis.

Patten SB, Marrie RA, Carta MG.

Int Rev Psychiatry. 2017 Oct;29(5):463-472. doi: 10.1080/09540261.2017.1322555. Epub 2017 Jul 6.

PMID:
28681616
49.

Markedly increased incidence of critical illness in adults with Type 1 diabetes.

Marrie RA, Sellers EAC, Chen H, Fransoo R, Bernstein CN, Hitchon CA, Peschken CA, Garland A.

Diabet Med. 2017 Oct;34(10):1414-1420. doi: 10.1111/dme.13404. Epub 2017 Jul 12.

PMID:
28626956
50.

Hospitalization is associated with subsequent disability in multiple sclerosis.

Garland A, Metz LM, Bernstein CN, Peschken CA, Hitchon CA, Marrie RA.

Mult Scler Relat Disord. 2017 May;14:23-28. doi: 10.1016/j.msard.2017.03.009. Epub 2017 Mar 24.

Supplemental Content

Loading ...
Support Center